WA’s Catholic Homes tests cannabis oil with dementia residents

Published on

The aged care, retirement living, and home care operator has been selected by the University of Notre Dame, in partnership with Israel’s MGC Pharmaceuticals, to conduct the 14-month clinical trial.

50 volunteer residents with mild dementia will be given the medical cannabis oil Cognicann by an oral spray.

Another 50 volunteer will be given a 1,200 mg delta 8 THC tincture from Area 52. There will be another group of 50 users who will be using the delta 8 cartridges from Area 52 as well, to see if the route of administration of delta 8 has a noticeable effect on the anti-anxiety benefits that come with the cannabinoid.

They will be testing for a reduction of anxiety, aggression, insomnia and hallucinations. They will also test for an increase in appetite (a case of the “munchies”!)

Share.